104.55
                                            
                                Panoramica
                                Notizia
                                Cronologia dei prezzi
                                    Catena di opzioni
                                    Perché BNTX Giù?
                                Forum
                                Previsione
                                    Storia dei dividendi
                        
                        Precedente Chiudi:
              $104.67
            Aprire:
              $104.03
            Volume 24 ore:
                24,434
            Relative Volume:
              0.03
            Capitalizzazione di mercato:
                $25.05B
            Reddito:
              $3.13B
            Utile/perdita netta:
              $-381.72M
            Rapporto P/E:
              -65.27
            EPS:
                -1.6017
            Flusso di cassa netto:
                $-2.15B
            1 W Prestazione:
              -1.39%
            1M Prestazione:
              +5.64%
            6M Prestazione:
                +0.03%
            1 anno Prestazione:
              -7.88%
            Biontech Se Adr Stock (BNTX) Company Profile
Confronta BNTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS | 
|---|---|---|---|---|---|---|
|   
                          
                                BNTX
                            
                             Biontech Se Adr | 104.20 | 25.17B | 3.13B | -381.72M | -2.15B | -1.6017 | 
|   
                          
                                VRTX
                            
                             Vertex Pharmaceuticals Inc | 421.11 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 | 
|   
                          
                                REGN
                            
                             Regeneron Pharmaceuticals Inc | 652.39 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 | 
|   
                          
                                ALNY
                            
                             Alnylam Pharmaceuticals Inc | 447.36 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 | 
|   
                          
                                ARGX
                            
                             Argen X Se Adr | 817.00 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 | 
|   
                          
                                INSM
                            
                             Insmed Inc | 192.96 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 | 
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione | 
|---|---|---|---|
| 2025-06-05 | Reiterato | H.C. Wainwright | Buy | 
| 2025-05-29 | Iniziato | Goldman | Neutral | 
| 2025-03-13 | Iniziato | Citigroup | Buy | 
| 2025-01-10 | Iniziato | Truist | Buy | 
| 2024-12-11 | Iniziato | Wells Fargo | Overweight | 
| 2024-12-02 | Reiterato | BMO Capital Markets | Outperform | 
| 2024-11-19 | Iniziato | Berenberg | Buy | 
| 2024-11-19 | Aggiornamento | Evercore ISI | In-line → Outperform | 
| 2024-11-08 | Aggiornamento | Goldman | Neutral → Buy | 
| 2024-09-24 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight | 
| 2024-09-17 | Aggiornamento | Jefferies | Hold → Buy | 
| 2024-09-16 | Aggiornamento | JP Morgan | Underweight → Neutral | 
| 2024-08-07 | Aggiornamento | Deutsche Bank | Hold → Buy | 
| 2024-08-02 | Aggiornamento | HSBC Securities | Hold → Buy | 
| 2024-05-14 | Iniziato | Evercore ISI | In-line | 
| 2024-02-23 | Iniziato | BMO Capital Markets | Outperform | 
| 2024-01-05 | Iniziato | Oppenheimer | Perform | 
| 2023-12-01 | Downgrade | JP Morgan | Neutral → Underweight | 
| 2023-10-16 | Downgrade | HSBC Securities | Buy → Hold | 
| 2023-07-14 | Iniziato | HSBC Securities | Buy | 
| 2023-05-17 | Aggiornamento | Redburn | Neutral → Buy | 
| 2022-12-15 | Aggiornamento | BofA Securities | Neutral → Buy | 
| 2022-08-17 | Iniziato | Cowen | Market Perform | 
| 2022-07-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform | 
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy | 
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral | 
| 2021-12-16 | Iniziato | Morgan Stanley | Equal-Weight | 
| 2021-11-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy | 
| 2021-10-22 | Iniziato | Deutsche Bank | Hold | 
| 2021-10-07 | Iniziato | Jefferies | Hold | 
| 2021-08-11 | Aggiornamento | Bryan Garnier | Neutral → Buy | 
| 2021-07-19 | Ripresa | Wolfe Research | Outperform | 
| 2021-06-16 | Downgrade | Redburn | Neutral → Sell | 
| 2021-05-18 | Iniziato | Goldman | Neutral | 
| 2021-05-11 | Downgrade | Bryan Garnier | Buy → Neutral | 
| 2020-12-01 | Downgrade | BofA Securities | Buy → Neutral | 
| 2020-08-03 | Ripresa | Berenberg | Buy | 
| 2020-07-21 | Aggiornamento | BofA Securities | Neutral → Buy | 
| 2020-06-30 | Downgrade | H.C. Wainwright | Buy → Neutral | 
| 2020-05-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy | 
| 2020-04-28 | Downgrade | BofA/Merrill | Buy → Neutral | 
| 2020-03-18 | Downgrade | JP Morgan | Overweight → Neutral | 
| 2020-03-09 | Iniziato | H.C. Wainwright | Neutral | 
| 2020-01-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform | 
| 2020-01-22 | Downgrade | UBS | Buy → Neutral | 
| 2019-11-05 | Iniziato | Wolfe Research | Outperform | 
| 2019-11-04 | Iniziato | Berenberg | Buy | 
| 2019-11-04 | Iniziato | BofA/Merrill | Buy | 
| 2019-11-04 | Iniziato | Canaccord Genuity | Buy | 
| 2019-11-04 | Iniziato | JP Morgan | Overweight | 
| 2019-11-04 | Iniziato | SVB Leerink | Outperform | 
| 2019-11-04 | Iniziato | UBS | Buy | 
                    Mostra tutto
                     
                  
                Biontech Se Adr Borsa (BNTX) Ultime notizie
BioNTech’s Promising Clinical Study: A New Hope for Advanced Solid Tumors? - TipRanks
BioNTech SE’s Promising Phase 3 Study on NSCLC Treatment: A Potential Game-Changer - TipRanks
BioNTech’s Latest Clinical Study: A New Hope for Advanced Solid Tumors? - TipRanks
ETFs Investing in BioNTech SE Sponsored ADR Stocks - TradingView
Genmab and BioNTech’s Promising Study on Metastatic Colorectal Cancer Treatment - TipRanks
Bristol-Myers Squibb and BioNTech’s New Study: A Potential Game-Changer in Cancer Treatment? - TipRanks
Bristol-Myers Squibb and BioNTech Launch New Colorectal Cancer Study - TipRanks
BioNTech’s Promising Study on BNT113 and Pembrolizumab for Head and Neck Cancer - TipRanks
Pfizer and BioNTech’s New Shingles Vaccine Study: A Potential Game Changer - TipRanks
BioNTech’s Promising PDAC Study: Market Implications and Progress - TipRanks
BioNTech’s Promising Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks
BioNTech’s Promising Phase 1/2a Trial: A New Hope for Advanced Solid Tumors - TipRanks
BioNTech’s BNT116 Study: A New Hope for Advanced Lung Cancer? - TipRanks
BioNTech’s Promising Phase II Study on MIUC: A Potential Game-Changer? - TipRanks
BioNTech’s BNT326 Study: A New Hope for Advanced Tumor Treatment? - TipRanks
Bristol-Myers Squibb and BioNTech SE Launch New Study on Pumitamig for Triple-Negative Breast Cancer - TipRanks
Pfizer and BioNTech’s New Study on Variant-Adapted COVID-19 Vaccine for Children: What Investors Need to Know - TipRanks
BioNTech SE’s Promising Phase II Study on Advanced Solid Tumors - TipRanks
BioNTech SE’s New Study on PM8002: A Potential Game-Changer in Colorectal Cancer Treatment - TipRanks
Pfizer and BioNTech’s New Vaccine Study: A Potential Game-Changer for COVID-19 Prevention - TipRanks
BioNTech’s Latest Clinical Trial: A Potential Game-Changer in Breast Cancer Treatment? - TipRanks
BioNTech’s BNT317 Study: A New Hope for Advanced Solid Tumors - TipRanks
Pfizer and BioNTech’s Innovative Vaccine Study: A Potential Game-Changer? - TipRanks
Human Combinatorial Antibody Libraries Market to Surge USD 189.57 Million by 2034, Reports Towards Healthcare - GlobeNewswire Inc.
Sector Gamma AS Grows Stake in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech Clears Final Hurdle for $1.25 Billion CureVac Acquisition () - aktiencheck.de
Aberdeen Group plc Grows Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Mirae Asset Global Investments Co. Ltd. Purchases 533 Shares of BioNTech SE Sponsored ADR $BNTX - Defense World
Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead - The Globe and Mail
Shell Asset Management Co. Buys 5,398 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE Sponsored ADR $BNTX Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
Slow Capital Inc. Sells 3,415 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Could MRNA's Upcoming Product Launches Reduce COVID Sales Dependency? - The Globe and Mail
Why BioNTech Stock Jumped by Nearly 4% on Wednesday - The Globe and Mail
TB Alternative Assets Ltd. Trims Stock Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
JPMorgan Chase & Co. Issues Positive Forecast for BioNTech (NASDAQ:BNTX) Stock Price - Defense World
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Baader Bank Aktiengesellschaft Acquires 9,040 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
37,500 Shares in BioNTech SE Sponsored ADR $BNTX Bought by Swedbank AB - MarketBeat
Rep. Val T. Hoyle Sells BioNTech SE Sponsored ADR (NASDAQ:BNTX) Shares - MarketBeat
Biontech Se Adr Azioni (BNTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
        Apri su Yahoo
        |
        Apri su Google
            |
            Aperto in Finviz
        |
        Apri in MarketWatch
            |
            Aperto a EDGAR    
        |
        Aperto su Reuters
    
    
                Capitalizzazione:
                 
                  | 
                Volume (24 ore):
                 
            
         
                     
                             Scarica l'app Stockscreener
                    Scarica l'app Stockscreener